Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis.

Aalbers CJ, Bevaart L, Loiler S, de Cortie K, Wright JF, Mingozzi F, Tak PP, Vervoordeldonk MJ.

PLoS One. 2015 Jun 24;10(6):e0130612. doi: 10.1371/journal.pone.0130612. eCollection 2015.

2.

Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02) Delivered via Intra-Articular Injection in Rhesus Monkeys with Collagen-Induced Arthritis.

Bevaart L, Aalbers CJ, Vierboom MP, Broekstra N, Kondova I, Breedveld E, Hauck B, Wright JF, Tak PP, Vervoordeldonk MJ.

Hum Gene Ther Clin Dev. 2015 Jun;26(2):103-12. doi: 10.1089/humc.2015.009.

PMID:
26086763
3.

SAFETY, BIODISTRIBUTION, AND EFFICACY OF AN AAV-5 VECTOR ENCODING HUMAN INTERFERON-BETA (ART-I02) DELIVERED VIA INTRA-ARTICULAR INJECTION IN RHESUS MONKEYS WITH COLLAGEN-INDUCED ARTHRITIS.

Bevaart L, Aalbers CC, Vierboom M, Broekstra N, Kondova I, Breedveld E, Hauck B, Wright F, Tak PP, Vervoordeldonk MJ.

Hum Gene Ther Clin Dev. 2015 May 13. [Epub ahead of print]

PMID:
25970762
4.

Two novel α7 nicotinic acetylcholine receptor ligands: in vitro properties and their efficacy in collagen-induced arthritis in mice.

van Maanen MA, Papke RL, Koopman FA, Koepke J, Bevaart L, Clark R, Lamppu D, Elbaum D, LaRosa GJ, Tak PP, Vervoordeldonk MJ.

PLoS One. 2015 Jan 24;10(1):e0116227. doi: 10.1371/journal.pone.0116227. eCollection 2015.

5.

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH.

Haematologica. 2011 Dec;96(12):1822-30. doi: 10.3324/haematol.2011.047159. Epub 2011 Aug 31.

6.

Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis?

Bevaart L, Vervoordeldonk MJ, Tak PP.

Arthritis Rheum. 2010 Aug;62(8):2192-205. doi: 10.1002/art.27503. Review. No abstract available.

7.

Collagen-induced arthritis in mice.

Bevaart L, Vervoordeldonk MJ, Tak PP.

Methods Mol Biol. 2010;602:181-92. doi: 10.1007/978-1-60761-058-8_11.

PMID:
20012399
8.

The Skn7 response regulator of Cryptococcus neoformans is involved in oxidative stress signalling and augments intracellular survival in endothelium.

Coenjaerts FE, Hoepelman AI, Scharringa J, Aarts M, Ellerbroek PM, Bevaart L, Van Strijp JA, Janbon G.

FEMS Yeast Res. 2006 Jun;6(4):652-61.

9.

The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma.

Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG, Leusen JH.

Cancer Res. 2006 Feb 1;66(3):1261-4.

10.

Direct targeting of genetically modified tumour cells to Fc gammaRI triggers potent tumour cytotoxicity.

Bevaart L, Goldstein J, Vitale L, Russoniello C, Treml J, Zhang J, Graziano RF, Leusen JH, van de Winkel JG, Keler T.

Br J Haematol. 2006 Feb;132(3):317-25.

PMID:
16409296
11.

CpG oligodeoxynucleotides enhance FcgammaRI-mediated cross presentation by dendritic cells.

Bevaart L, Van Ojik HH, Sun AW, Sulahian TH, Leusen JH, Weiner GJ, Van De Winkel JG, Van Vugt MJ.

Int Immunol. 2004 Aug;16(8):1091-8. Epub 2004 Jun 10.

PMID:
15192052
12.

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ.

Cancer Res. 2003 Sep 1;63(17):5595-600.

13.

Liposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response.

Arigita C, Bevaart L, Everse LA, Koning GA, Hennink WE, Crommelin DJ, van de Winkel JG, van Vugt MJ, Kersten GF, Jiskoot W.

Infect Immun. 2003 Sep;71(9):5210-8.

Supplemental Content

Loading ...
Support Center